2-(2-甲基-3H-咪唑-4-基)乙胺 | 34392-54-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(2-甲基-3H-咪唑-4-基)乙胺
• 英文名称: 2-Methylhistamine
• 英文别名: 2-(2-methyl-1H-imidazol-5-yl)ethanamine
• CAS: 34392-54-6
• 化学式: C₆H₁₁N₃
• 分子量: 125.173
• InChiKey: XDKYTXBAVJELDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  347.5±17.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.7
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为产物：
  描述：

  Z-1,2,4-Tris(benzamido)butene 、 乙酸酐 生成 2-(2-甲基-3H-咪唑-4-基)乙胺
  参考文献：
  名称：

  van der Merwe, Hoppe-Seyler's Zeitschrift fur Physiologische Chemie, 1928, vol. 177, p. 305

  摘要：

  DOI：

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE
  申请人：ADOCIA

  公开号：US20190275156A1

  公开（公告）日：2019-09-12

  Physically stable compositions in the form of an injectable aqueous solution, wherein the pH is from 6.0 to 8.0, includes at least: a) human glucagon and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy. In one embodiment, the compositions further comprise a gut hormone.

  在形式为可注射的水溶液中，具有稳定的物理性质，其中pH值为6.0至8.0，至少包括： a) 人类胰高血糖素和 b) 具有羧酸基团和疏水基团Hy的共聚氨基酸。在一个实施例中，这些组合物进一步包括一种肠道激素。
• CXCR4 chemokine receptor binding comounds
  申请人：——

  公开号：US20040209921A1

  公开（公告）日：2004-10-21

  The present invention relates to compounds that bind to chemokine receptors, and having the formula 1 wherein each A, X, Y, R 1 , R 2 and R 3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

  本发明涉及与趋化因子受体结合的化合物，其具有式1的结构，其中A、X、Y、R1、R2和R3均为取代基。本发明还涉及使用这类化合物的方法，例如在治疗HIV感染和炎症性疾病如类风湿性关节炎中的应用。此外，本发明还涉及使用这类化合物来提高祖细胞和干细胞计数的方法，以及提高白细胞计数的方法。
• COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID
  申请人：ADOCIA

  公开号：US20190275110A1

  公开（公告）日：2019-09-12

  Physically stable compositions in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, having at least: human glucagon and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, in one embodiment, the compositions according to the invention further includes a gastrointestinal hormone.

  物理上稳定的组合物以可注射的水溶液形式存在，其pH值为6.0至8.0，至少包括：人胰高血糖素和带有羧基电荷和疏水基团Hy的共聚氨基酸，在一种实施方式中，根据本发明的组合物进一步包括肠道激素。
• Compositions and methods for enhancing drug delivery across biological membranes and tissues
  申请人：——

  公开号：US20020009491A1

  公开（公告）日：2002-01-24

  This invention provides compositions and methods for enhancing delivery of drugs and other agents across a biological barrier, including epithelial tissues such as the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 50 residues in length.

  本发明提供了增强药物和其他药剂跨越生物屏障的组合物和方法，包括上皮组织例如皮肤、胃肠道、肺上皮等。该组合物和方法也适用于通过内皮组织跨越血脑屏障。该组合物和方法采用了具有足够的鸟氨酸或酰胺基侧链基团的增强运输体，以增强化合物跨越组织的一个或多个层次的递送，相对于非结合化合物。增强递送的聚合物包括例如在6到50个残基之间的聚精氨酸分子。